VERA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Vera Therapeutics Reports Third Quarter 2026 Financial Results and Provides TRUTAKNA Business Update

Nov 5, 2026

8-K

Vera Therapeutics Announces TRUTAKNA™ Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Neph

Sep 15, 2026

8-K

Vera Therapeutics Announces FDA Accelerated Approval and Commercial Launch of TRUTAKNA™ for IgA Nephropathy

Aug 10, 2026

8-K

Vera Therapeutics Announces Executive Leadership Transition in Regulatory Affairs

Jul 9, 2026

8-K

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ (atacicept-vymj)

Jul 7, 2026

8-K

Vera Therapeutics Aligns with FDA on Accelerated ORIGIN 3 eGFR Analysis Plan for Atacicept

Jun 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

FIXED PRICE OFFERING - CLASS A COMMON STOCK | Offering amount: $260,869,590 | Shares: 6,138,108 | Price: $42.500 | Bank: J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI, Cantor

Dec 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $200,000,000 | Bank: J.P. Morgan

Dec 8, 2025

424B5

August 2025 ATM

Aug 5, 2025

424B5

SHELF OFFERING | Shares amount: 7,142,858 | Share price: $42.00 | Offering amount: $300,000,036.00 | Bank: J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI, Cantor

Oct 30, 2024

424B5

.00 | Offering amount: $300,000,000.00 | Bank: J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI, Cantor

Oct 29, 2024

424B5

SHELF OFFERING | Shares amount: 8,064,517 | Share price: $31.00 | Offering amount: $250,000,027.00 | Bank: J.P. Morgan, TD Cowen, Evercore ISI, LifeSci Capital

Jan 30, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2025

S-3ASR

SHELF

Oct 28, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 27, 2024

S-3MEF

Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]

Jan 29, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 28, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 3, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 3, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Fordyce Marshall (Reporting)

Sep 17, 2026

Young Joseph R (Reporting)

Sep 14, 2026

Fordyce Marshall (Reporting)

Sep 4, 2026

144

Form 144 - Report of proposed sale of securities

Sep 2, 2026

SCHEDULE 13G/A

Kynam Capital Management, LP (Filed by)

Aug 14, 2026

4/A

Fordyce Marshall (Reporting)

Aug 12, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 14, 2022

LETTER

Form UPLOAD - SEC-generated letter

Jun 9, 2022

CORRESP

Form CORRESP - Correspondence

Jun 9, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 10, 2022

CORRESP

Form CORRESP - Correspondence

Feb 7, 2022

CORRESP

Form CORRESP - Correspondence

Feb 7, 2022

Vera Therapeutics, Inc. VERA · SEC Filings